- Nektar Therapeutics (NASDAQ:NKTR): Q3 GAAP EPS of -$0.61 beats by $0.16.
- Revenue of $30M (+2.7% Y/Y) beats by $7.18M.Revenue was higher due to the recognition of $50.0M in total milestones from Bristol-Myers Squibb related to the start of two new registrational trials of bempegaldesleukin plus Opdivo® in adjuvant melanoma and muscle-invasive bladder cancer.
- Product sales: $5.7M (+1.8%).
- Cash and investments in marketable securities of ~$1.2B.
- Press Release
Nektar Therapeutics EPS beats by $0.16, beats on revenue
Recommended For You
More Trending News
About NKTR Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
NKTR | - | - |
Nektar Therapeutics |